Incyte's INCA033989 shows spleen, symptom and anemia responses in Phase 1 myelofibrosis studies
INCY•INCY•INCY•INCY•Incyte said Phase 1 studies of INCA033989 showed improvements in spleen enlargement, symptoms and anemia in myelofibrosis patients, with favorable tolerability among those without prior JAK-inhibitor treatment. The company will present hematology data at the American Society of Hematology meeting on December 12-15, 2026.
Phase 1 results for INCA033989 showed improvements in spleen enlargement, symptoms and anemia in myelofibrosis patients. The drug had favorable tolerability in patients who had not previously received a JAK inhibitor.
In essential thrombocythemia, Phase 1 studies showed molecular responses and restoration of normal blood cell production. Incyte also plans to present long-term Phase 1/2 latarcibart results assessing bleeding prevention in adolescents and adults with von Willebrand disease.
